OncLive TV

James J. Harding, MD, discusses efficacy data with nivolumab plus ipilimumab that led to this regimen’s FDA approval for unresectable or metastatic hepatocellular carcinoma

Jonathan Strosberg, MD, discusses how the phase 2 DAREON-5 trial could address questions about the use of DLL3/CD3-targeted agents in SCLC and other NECs.

Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.

Justin Moser, MD, discusses key considerations for second-line treatment selection for patients with melanoma who have progressed on PD-1 inhibitors.

Evan T. Hall, MD, MPhil, discusses the evolving evidence base surrounding ICI continuation and rechallenge strategies in the second-line treatment of metastatic renal cell carcinoma.

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.

Vivek G Patel, MD, discusses the comparative efficacy and safety profiles of mosunetuzumab and epcoritamab in follicular lymphoma.

Sophie Paczesny MD, PhD, discussed the ability of ST2 to predict the risk of developing aGVHD or death following transplant.

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

Thierry André, MD, discusses the safety profile of nivolumab/ipilimumab for the treatment of patients with MSI-H/dMMR metastatic colorectal cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast cancer.

R. Lor Randall, MD, FASCO, discussed the development and application of three-dimensional spheroid models for high-throughput drug screening in osteosarcoma research.

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

Dana M. Chase, MD, discusses how patient preferences can inform treatment planning in gynecologic oncology.

Stergios J. Moschos, MD, discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma.

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.

Nicole Lamanna, MD, shares key considerations for the use of pirtobrutinib in the management of chronic lymphocytic leukemia.

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Jia Luo, MD, discusses ctDNA outcomes following treatment of daraxonrasib in ctDNA-evaluable patients with RAS G12X–mutant advanced NSCLC.

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Pietro Scilipoti, MD, discusses the need for better life expectancy assessment to guide prostate cancer treatment strategies.

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.